Project summary
The goal of this project is to apply the bispecific antibody (BsAb) platform technology developed by CI Howard as a novel molecular tool to target and deliver mRNA-based therapeutic products such as vaccines to specific cell targets. As a proof of principle study, this project will use BsAbs to target mRNA vaccines to specific cell receptors on dendritic cells (DCs) to improve vaccine efficacy by enhancing the first step of the immune response and duration of that response for the treatment of infectious diseases aligned with the Sanofi Translational Science Hub (TSH).
